The importance of accuracy in HER2 testing.
Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Ana Maria
AM
Gonzalez-Angulo
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016477:Artifacts; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry / Q000592:standards; D017404:In Situ Hybridization, Fluorescence / Q000592:standards*; D060787:Neoplasm Grading; D015588:Observer Variation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human